Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin
Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin
复制标题
DOI：
10.1016/j.humimm.2005.01.032
复制
发表时间：
2005-04-01
期刊：
影响因子：
2.7
通讯作者：
Leffell, MS
中科院分区：
文献类型：
--
作者：
Zachary, AA;Montgomery, RA;Leffell, MS
抗供者HLA抗原抗体是影响同种异体移植获得和预后的重要障碍。已经进行了许多尝试来用HLA特异性抗体使患者脱敏，但最有效和持久的是用高剂量汇集的人静脉内免疫球蛋白（IVIg）以及血浆置换和低剂量IVIg的组合进行治疗。尽管这些治疗取得了成功，但一些患者的供者特异性抗体（DSA）水平仍然很低。我们研究了可能与DSA相关并用于预测DSA消除的因素。最显著的相关性是治疗开始时的抗体强度和抗体特异性，尽管其他因素显示了相关性的趋势。我们演示了如何在这里生成的数据类型可以用来预测消除或持久的DSA。(c)美国组织相容性和免疫遗传学学会，2005年。爱思唯尔公司出版
Antibody to donor HLA antigens is a significant barrier to both access to and outcome of allogeneic transplants. Many attempts have been made to desensitize patients with HLA-specific antibody, but the most effective and durable have been treatment with high-dose pooled human intravenous immunoglobulin (lVIg) and a combination of plasmapheresis and low-dose IVIg. Despite the success of these treatments, low levels of donor-specific antibody (DSA) persist in some patients. We examined factors that may be related to and used to predict the elimination of DSA. The most significant associations have been strength of antibody at initiation of treatment and antibody specificity, although other factors revealed a trend toward association. We demonstrate how the types of data generated here can be used to predict elimination or persistence of DSA. (c) American Society for Histocompatibility and Immunogenetics, 2005. Published by Elsevier Inc.